Home > Oncology > WCLC 2018 > Unmet needs in surgical management of malignant pleural mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is an aggressive and highly lethal cancer. Combined treatment with two cancer immunotherapy drugs significantly prolonged survival in mouse models of MPM [1]. Recent findings from The Cancer Genome Atlas Research Network provided both a rationale and a biomarker for clinical trials of emerging anti-VISTA immunotherapies [2]. Use of high-throughput technologies to characterise the genomic and epigenetic landscapes of mesothelioma may drive advances in novel clinical treatments [3].

“There are lots of needs in the surgical management of mesothelioma,” said Dr Valerie Rusch (Memorial Sloan-Kettering Cancer Center, USA). She cited many opinions, only modest amounts of data, and even less standardisation.

The minimal acceptable standards for optimal biopsy and staging are controversial, said Dr Rusch. Questions center on whether surgical biopsy (VATS) is always required and how many sites should be biopsied to account for tumour heter...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on